Prevalence of medication nonadherence to co-medication compared to immunosuppressants in heart transplant recipients: findings from the international cross-sectional BRIGHT study
Purpose - To assess and compare the prevalence of medication nonadherence (MNA) (implementation and persistence) to immunosuppressants and co-medications in heart transplant recipients. - Methods - MNA prevalence was assessed using the Basel Assessment of Adherence to Immunosuppressive Medications S...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2019
|
| In: |
Clinical therapeutics
Year: 2018, Jahrgang: 41, Heft: 1, Pages: 130-136 |
| ISSN: | 1879-114X |
| DOI: | 10.1016/j.clinthera.2018.11.007 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.clinthera.2018.11.007 Verlag: http://www.sciencedirect.com/science/article/pii/S0149291818305617 
|
| Verfasserangaben: | Remon Helmy, PhD, Samira Scalso de Almeida, Msc, Kris Denhaerynck, PhD, Lut Berben, PhD, Fabienne Dobbels, PhD, Cynthia L. Russell, PhD, Bartira de Aguiar Roza, PhD, and Sabina De Geest, PhD, on behalf of the BRIGHT study team |
| Zusammenfassung: | Purpose - To assess and compare the prevalence of medication nonadherence (MNA) (implementation and persistence) to immunosuppressants and co-medications in heart transplant recipients. - Methods - MNA prevalence was assessed using the Basel Assessment of Adherence to Immunosuppressive Medications Scale (self-report) and compared using logistic regression in a 4-continent sample of 1397 heart transplant recipients from 36 heart transplant centers in 11 countries. - Findings - MNA was significantly (α = 0.05) higher to co-medications than to immunosuppressants (taking nonadherence: 23.9% vs 17.3%; odds ratio [OR] = 1.5; 95% CI, 1.30-1.73; drug holiday: 5.7% vs 1.9%; OR = 3.17; 95% CI, 2.13-4.73; dose alteration: 3.8% vs 1.6%; OR = 2.46; 95% CI, 1.49-4.06; and discontinuation: 2.6% vs 0.5%; OR = 5.15; 95% CI, 2.36-11.20). - Implications - The observed MNA necessitates adherence-enhancing interventions encompassing the entire post-heart transplant medication regimen. ClinicalTrials.gov identifier: NCT01608477. |
|---|---|
| Beschreibung: | Available online 24 December 2018 Gesehen am 15.11.2019 The BRIGHT study team ... Andreas Doesch |
| Beschreibung: | Online Resource |
| ISSN: | 1879-114X |
| DOI: | 10.1016/j.clinthera.2018.11.007 |